Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meropenem: a microbiological overview

J R Edwards1

  • 1Infection Research Department, Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK.

The Journal of Antimicrobial Chemotherapy
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.

Nature communications·2024
Same author

Image-Guided Transvaginal and Transabdominal Drain Placement for Surgical Navigation in a Patient with Tubo-Ovarian Abscess and Obstructed Hemivagina and Ipsilateral Renal Anomaly Syndrome.

Journal of pediatric and adolescent gynecology·2021
Same author

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo.

Molecular cancer·2017
Same author

Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer.

Oncogene·2016
Same author

Persistence of Influenza A (H1N1) Virus on Stainless Steel Surfaces.

Applied and environmental microbiology·2016
Same author

MS2 Coliphage as a Surrogate for 2009 Pandemic Influenza A (H1N1) Virus (pH1N1) in Surface Survival Studies on N95 Filtering Facepiece Respirators.

Journal of the International Society for Respiratory Protection·2015
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Meropenem exhibits broad-spectrum bactericidal activity against most bacteria, including Pseudomonas aeruginosa and Enterobacteriaceae. Its efficacy is supported by in vitro data and animal studies, predicting successful treatment for various infections.

Area of Science:

  • Pharmacology and Microbiology
  • Antibiotic Resistance
  • Infectious Diseases

Background:

  • Meropenem is a carbapenem antibiotic with broad-spectrum bactericidal activity.
  • Its effectiveness stems from bacterial cell entry and affinity for penicillin-binding proteins.
  • Meropenem is stable against serine-based beta-lactamases, enhancing its spectrum of activity.

Purpose of the Study:

  • To evaluate the in vitro and in vivo activity of meropenem.
  • To compare meropenem's spectrum with imipenem.
  • To assess meropenem's potential for treating various infections.

Main Methods:

  • In vitro susceptibility testing against clinical pathogens.
  • Comparison of meropenem and imipenem activity.

Related Experiment Videos

  • Evaluation in guinea pig models of systemic and localized infections.

    • Main Results:

    • Meropenem shows excellent activity against most aerobes and anaerobes.
    • It is more active than imipenem against Pseudomonas aeruginosa, Enterobacteriaceae, and Haemophilus influenzae.
    • Clinical susceptibility is defined by MICs ≤ 4 mg/L and growth inhibition zones ≥ 14 mm.

    Conclusions:

    • Meropenem demonstrates broad-spectrum activity and stability against beta-lactamases.
    • In vitro and animal studies predict meropenem's efficacy in treating diverse infections.
    • Achieved therapeutic concentrations support meropenem's use across multiple body sites.